Michael O'Grady
Chairman and CEO at Northern Trust Corporation
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Northern Trust Corporation, 3 years.
Chief executive roles
Solid · grade C
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 50% of the scoring weight is on file.
- Dividends 15%
- 80
- Revenue growth 20%
- 61
- Earnings growth 15%
- 70
dividend grew 8.6% a year
4.9% a year in revenue
7.5% a year in earnings per share
50% of the scoring weight is on file. Figures cover December 2017 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Abbott Laboratories April 24, 202697.6%
-
Northern Trust Corporation April 21, 202695.8%
-
Abbott Laboratories April 25, 202598.0%
-
Northern Trust Corporation April 22, 202595.6%
-
Abbott Laboratories April 26, 202498.5%
-
Northern Trust Corporation April 16, 202495.0%
-
Abbott Laboratories April 28, 202399.5%
-
Northern Trust Corporation April 25, 202396.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 3, 2026 | Northern Trust Corporation | Shares withheld for tax | −787 | $171.78 | $135,191 |
| Apr 24, 2026 | Abbott Laboratories | Grant or award | +2,286 | — | — |
| Mar 1, 2026 | Northern Trust Corporation | Shares withheld for tax | −11,129 | $143.15 | $1,593,116 |
| Feb 17, 2026 | Northern Trust Corporation | Grant or award | +72,642 | — | — |
| Feb 17, 2026 | Northern Trust Corporation | Shares withheld for tax | −32,181 | $147.24 | $4,738,330 |
| Feb 5, 2026 | Northern Trust Corporation | Grant or award | +19,437 | — | — |
| Jan 29, 2026 | Northern Trust Corporation | Option exercise | +34,489 | $58.25 | $2,008,984 |
| Jan 29, 2026 | Northern Trust Corporation | Shares withheld for tax | −21,739 | $150.78 | $3,277,806 |
| Dec 3, 2025 | Northern Trust Corporation | Shares withheld for tax | −770 | $131.32 | $101,116 |
| Apr 25, 2025 | Abbott Laboratories | Grant or award | +1,635 | — | — |
| Mar 1, 2025 | Northern Trust Corporation | Shares withheld for tax | −11,684 | $110.27 | $1,288,395 |
| Feb 18, 2025 | Northern Trust Corporation | Grant or award | +63,107 | — | — |
| Feb 18, 2025 | Northern Trust Corporation | Shares withheld for tax | −27,957 | $112.69 | $3,150,474 |
| Feb 5, 2025 | Northern Trust Corporation | Grant or award | +19,012 | — | — |
| Jan 30, 2025 | Northern Trust Corporation | Option exercise | +23,739 | $70.21 | $1,666,715 |
Questions about Michael O'Grady
What boards is Michael O'Grady on?
Michael O'Grady sits on the boards of Abbott Laboratories and Northern Trust Corporation.
What company is Michael O'Grady the CEO of?
Michael O'Grady has been Chairman and CEO of Northern Trust Corporation since January 2018.
How long has Michael O'Grady served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.